References
1. Shukla A, Shreshtha A, Mukund A, et al. Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int . 2021;15(3):531-567. doi:10.1007/s12072-021-10189-42. Aydinli M, Bayraktar Y. Budd-Chiari syndrome: etiology, pathogenesis and diagnosis. World J Gastroenterol . 2007;13(19):2693-2696. doi:10.3748/wjg.v13.i19.26933. Lupasco I, Dumbrava VT. Diagnosis and therapy of Budd Chiari syndrome.Med Pharm Rep . 2021;94(Suppl No 1):S68-S71. doi:10.15386/mpr-22354. Aydinli M. Budd-Chiari syndrome: Etiology, pathogenesis and diagnosis. World J Gastroenterol . 2007;13(19):2693. doi:10.3748/wjg.v13.i19.26935. Darwish Murad S, Plessier ; Aurelie, Manuel Hernandez-Guerra ;, et al. Etiology, Management, and Outcome of the Budd-Chiari Syndrome .; 2009.6. Găman MA, Cozma MA, Manan MR, et al. Budd-Chiari syndrome in myeloproliferative neoplasms: A review of literature. World J Clin Oncol . 2023;14(3):99-116. doi:10.5306/wjco.v14.i3.997. Goel RM, Johnston EL, Patel K V, Wong T. Budd–Chiari syndrome: investigation, treatment and outcomes. Postgrad Med J . 2015;91(1082):692-697. doi:10.1136/postgradmedj-2015-1334028. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol . 2016;64(1):179-202. doi:10.1016/j.jhep.2015.07.0409. Khan F, Armstrong MJ, Mehrzad H, et al. Review article: a multidisciplinary approach to the diagnosis and management of Budd-Chiari syndrome. Aliment Pharmacol Ther . 2019;49(7):840-863. doi:10.1111/apt.1514910. Betterle C, Presotto F, Furmaniak J. Epidemiology, pathogenesis, and diagnosis of Addison’s disease in adults. J Endocrinol Invest . 2019;42(12):1407-1433. doi:10.1007/s40618-019-01079-611. Wei L, Macdonald TM, Walker BR. Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease Background: Glucocorticoids Have Adverse Systemic Effects, In .; 2004.12. Riley DS, Barber MS, Kienle GS, et al. CARE guidelines for case reports: explanation and elaboration document. J Clin Epidemiol . 2017;89:218-235. doi:10.1016/j.jclinepi.2017.04.02613. Munir S, Quintanilla Rodriguez BS, Waseem M. Addison Disease. [Updated 2023 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441994/.14. Zhao R, Luo S, Wang S, Wen Y, Xiong F. Coronary artery disease in a patient with Addison’s disease: a case report and literature review. BMC Cardiovasc Disord. 2023 Jan 29;23(1):54. doi: 10.1186/s12872-023-03079-0.15. Mozolevska V, Schwartz A, Cheung D, Shaikh B, Bhagirath KM, Jassal DS. Addison’s Disease and Dilated Cardiomyopathy: A Case Report and Review of the Literature. Case Rep Cardiol. 2016;2016:4362514. doi: 10.1155/2016/4362514.16. Irving I. Goodof, Cyril M. Macbryde, Heart Failure in Addison’s Disease with Myocardial Changes of Potassium Deficiency, The Journal of Clinical Endocrinology & Metabolism, Volume 4, Issue 1, 1 January 1944, Pages 30–34, https://doi.org/10.1210/jcem-4-1-3.17. Plessier A, Valla DC. Budd-Chiari Syndrome. Semin Liver Dis. 2008 Aug 23;28(03):259–69.18. Mederacke I, Helfritz F, Puls F, Ringe KI, Klempnauer J, Manns MP, Strassburg CP. Budd-Chiari syndrome after treatment with budesonide in a cirrhotic patient with autoimmune hepatitis. Ann Hepatol. 2012 Jan-Feb;11(1):143-4.19. Lewis JH, Tice HL, Zimmerman HJ. Budd-Chiari syndrome associated with oral contraceptive steroids. Review of treatment of 47 cases. Dig Dis Sci. 1983 Aug;28(8):673-83. doi: 10.1007/BF01312555.20. Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology. 2003 Jul;38(1):196-202. doi: 10.1053/jhep.2003.50266.21. McDow AD, Gurung A, Poola R, Fratianni C, Garfinkel M, Jakoby MG. Portal Vein Thrombosis in the Setting of Newly Diagnosed Cushing’s Syndrome.J Investig Med High Impact Case Rep . 2017;5(2):2324709617703672. doi:10.1177/2324709617703672